|
1
|
Ambrose JA and Singh M: Pathophysiology of
coronary artery disease leading to acute coronary syndromes.
F1000Prime Rep. 7:082015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hausenloy DJ and Yellon DM: Myocardial
ischemia-reperfusion injury: A neglected therapeutic target. J Clin
Invest. 123:92–100. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Groot H and Rauen U:
Ischemia-reperfusion injury: Processes in pathogenetic networks: A
review. Transplant Proc. 39:pp. 481–484. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boag SE, Das R, Shmeleva EV, Bagnall A,
Egred M, Howard N, Bennaceur K, Zaman A, Keavney B and
Spyridopoulos I: T lymphocytes and fractalkine contribute to
myocardial ischemia/reperfusion injury in patients. J Clin Invest.
125:3063–3076. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zitta K, Meybohm P, Bein B, Gruenewald M,
Lauer F, Steinfath M, Cremer J, Zacharowski K and Albrecht M:
Activities of cardiac tissue matrix metalloproteinases 2 and 9 are
reduced by remote ischemic preconditioning in cardiosurgical
patients with cardiopulmonary bypass. J Transl Med. 12:942014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He K, Yan L, Pan CS, Liu YY, Cui YC, Hu
BH, Chang X, Li Q, Sun K, Mao XW, et al: ROCK-dependent ATP5D
modulation contributes to the protection of notoginsenoside NR1
against ischemia-reperfusion-induced myocardial injury. Am J
Physiol Heart Circ Physiol. 307:H1764–H1776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sawicki G: Synergistic effect of
inhibitors of MMPs and ROS-dependent modifications of contractile
proteins on protection hearts subjected to oxidative stress. Curr
Pharm Des. 20:1345–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukumoto S: Actions and mode of actions of
FGF19 subfamily members. Endocr J. 55:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wente W, Efanov AM, Brenner M,
Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I,
Zitzer H and Gromada J: Fibroblast growth factor-21 improves
pancreatic beta-cell function and survival by activation of
extracellular signal-regulated kinase 1/2 and Akt signaling
pathways. Diabetes. 55:2470–2478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu SQ, Roberts D, Kharitonenkov A, Zhang
B, Hanson SM, Li YC, Zhang LQ and Wu YH: Endocrine protection of
ischemic myocardium by FGF21 from the liver and adipose tissue. Sci
Rep. 3:27672013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ge X, Chen C, Hui X, Wang Y, Lam KS and Xu
A: Fibroblast growth factor 21 induces glucose transporter-1
expression through activation of the serum response factor/Ets-like
protein-1 in adipocytes. J Biol Chem. 286:34533–34541. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Syrjälä SO, Tuuminen R, Nykänen AI,
Raissadati A, Dashkevich A, Keränen MA, Arnaudova R, Krebs R, Leow
CC, Saharinen P, et al: Angiopoietin-2 inhibition prevents
transplant ischemia-reperfusion injury and chronic rejection in rat
cardiac allografts. Am J Transplant. 14:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lukasz A, Beutel G, Kümpers P, Denecke A,
Westhoff-Bleck M, Schieffer B, Bauersachs J, Kielstein JT and
Tutarel O: Angiopoietin-2 in adults with congenital heart disease
and heart failure. PLoS One. 8:e668612013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pöss J, Ukena C, Kindermann I, Ehrlich P,
Fuernau G, Ewen S, Mahfoud F, Kriechbaum S, Böhm M and Link A:
Angiopoietin-2 and outcome in patients with acute decompensated
heart failure. Clin Res Cardiol. 104:380–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scholz A, Plate KH and Reiss Y:
Angiopoietin-2: A multifaceted cytokine that functions in both
angiogenesis and inflammation. Ann NY Acad Sci. 1347:45–51. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Winter SF, Acevedo VD, Gangula RD, Freeman
KW, Spencer DM and Greenberg NM: Conditional activation of FGFR1 in
the prostate epithelium induces angiogenesis with concomitant
differential regulation of Ang-1 and Ang-2. Oncogene. 26:4897–4907.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu Z, Chen Y, Li L, Wang G, Xue H and Tang
W: Combination therapy of renin-angiotensin system inhibitors plus
calcium channel blockers versus other two-drug combinations for
hypertension: A systematic review and meta-analysis. J Hum
Hypertens. 31:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yellon DM and Hausenloy DJ: Myocardial
reperfusion injury. N Engl J Med. 357:1121–1135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu SQ, Tefft BJ, Roberts DT, Zhang LQ,
Ren Y, Li YC, Huang Y, Zhang D, Phillips HR and Wu YH:
Cardioprotective proteins upregulated in the liver in response to
experimental myocardial ischemia. Am J Physiol Heart Circ Physiol.
303:H1446–H1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu SQ and Wu YH: Liver cell-mediated
alleviation of acute ischemic myocardial injury. Front Biosci
(Elite Ed). 2:711–724. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Planavila A, Redondo-Angulo I and
Villarroya F: FGF21 and Cardiac Physiopathology. Front Endocrinol
(Lausanne). 6:1332015.PubMed/NCBI
|
|
23
|
Patel V, Adya R, Chen J, Ramanjaneya M,
Bari MF, Bhudia SK, Hillhouse EW, Tan BK and Randeva HS: Novel
insights into the cardio-protective effects of FGF21 in lean and
obese rat hearts. PLoS One. 9:e871022014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cong WT, Ling J, Tian HS, Ling R, Wang Y,
Huang BB, Zhao T, Duan YM, Jin LT and Li XK: Proteomic study on the
protective mechanism of fibroblast growth factor 21 to
ischemia-reperfusion injury. Can J Physiol Pharmacol. 91:973–984.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Li H, Wei R, Ma J, Zhao Y, Lian Z
and Liu Z: Endothelial cells regulate cardiac myocyte
reorganisation through β1-integrin signalling. Cell Physiol
Biochem. 35:1808–1820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qian H, Yang Y, Li J, Huang J, Dou K and
Yang G: The role of vascular stem cells in atherogenesis and
post-angioplasty restenosis. Ageing Res Rev. 6:109–127. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanajak P, Chattipakorn SC and
Chattipakorn N: Effects of fibroblast growth factor 21 on the
heart. J Endocrinol. 227:R13–R30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji K, Zheng J, Lv J, Xu J, Ji X, Luo YB,
Li W, Zhao Y and Yan C: Skeletal muscle increases FGF21 expression
in mitochondrial disorders to compensate for energy metabolic
insufficiency by activating the mTOR-YY1-PGC1α pathway. Free Radic
Biol Med. 84:161–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moyers JS, Shiyanova TL, Mehrbod F, Dunbar
JD, Noblitt TW, Otto KA, Reifel-Miller A and Kharitonenkov A:
Molecular determinants of FGF-21 activity-synergy and cross-talk
with PPARgamma signaling. J Cell Physiol. 210:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fiedler U, Krissl T, Koidl S, Weiss C,
Koblizek T, Deutsch U, Martiny-Baron G, Marmé D and Augustin HG:
Angiopoietin-1 and angiopoietin-2 share the same binding domains in
the Tie-2 receptor involving the first Ig-like loop and the
epidermal growth factor-like repeats. J Biol Chem. 278:1721–1727.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lorbeer R, Baumeister SE, Dörr M, Nauck M,
Grotevendt A, Volzke H, Vasan RS, Wallaschofski H and Lieb W:
Circulating angiopoietin-2, its soluble receptor Tie-2, and
mortality in the general population. Eur J Heart Fail.
15:1327–1334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Yong H, Mi L, Bai Y, Guo L, Gao W,
Cui M and Zhang Y: Changes and significance of serum angiopoietin-2
levels in patients with coronary heart disease. Biomarkers.
17:745–749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Piccolo MT, Menale C and Crispi S:
Combined anticancer therapies: An overview of the latest
applications. Anticancer Agents Med Chem. 15:408–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smith R, McCready T and Yusuf S:
Combination therapy to prevent cardiovascular disease: Slow
progress. JAMA. 309:1595–1596. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cadete VJ, Arcand SA, Lin HB and Sawicki
G: Synergistic protection of MLC 1 against cardiac
ischemia/reperfusion-induced degradation: A novel therapeutic
concept for the future. Future Med Chem. 5:389–398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
